Inhaled dry powder formulations for treating tuberculosis

Current Drug Delivery

Volumn 12, Issue 1, 2015, Pages 26-39

  Das, Shyamal ^a   Tucker, Ian ^a   Stewart, Peter ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Dry powder inhaler; Microparticles; Powder formulation; Pulmonary delivery; Spray drying; Tuberculosis

Indexed keywords

AMINOSALICYLIC ACID; CAPREOMYCIN; ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; NANOPARTICLE; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE; TUBERCULOSTATIC AGENT; AEROSOL; DRUG COMBINATION; POWDER;

ARTICLE; CONTROLLED DRUG RELEASE; CRYSTALLIZATION; DRUG DELIVERY DEVICE; DRUG FORMULATION; DRY POWDER INHALER; FREEZE DRYING; LUNG ALVEOLUS MACROPHAGE; MATERIAL COATING; PATHOGENESIS; PRIORITY JOURNAL; SPRAY DRYING; TUBERCULOSIS; AEROSOL; ANIMAL; CHEMISTRY; DEVICES; DRUG COMBINATION; DRUG DELIVERY SYSTEM; DRUG EFFECTS; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG; MEDICINAL CHEMISTRY; MICROBIOLOGY; PARTICLE SIZE; PATHOPHYSIOLOGY; PHARMACEUTICS; POWDER; PROCEDURES; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; ANTITUBERCULAR AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; HUMANS; LUNG; PARTICLE SIZE; POWDERS; TECHNOLOGY, PHARMACEUTICAL; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84930882680     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: 10.2174/1567201811666140716123050     Document Type: Article

References (128)

1. Frieden, T. R., Sterling, T. R., Munsiff, S. S., Watt, C. J., Dye, C. Tuberculosis. Lancet, 2003, 362, 887-899.
2. Hanif, S. N. M., Garcia-Contreras, L. Pharmaceutical aerosols for the treatment and prevention of Tuberculosis. Front. Cell. Infect. Microbiol., 2012, 2, 11.
3. World Health Organization. Global tuberculosis report 2012. WHO/HTM/TB/2012. 6.
4. Zhang, D., Lu, Y., Liu, K., Liu, B., Wang, J., Zhang, G., Zhang, H., Liu, Y., Wang, B., Zheng, M. Fu, L., Hou, Y., Gong, N., Lv, Y., Li, C., Cooper, C. B., Upton, A. M., Yin, D., Ma, Z., Huang, H. Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis. J. Med. Chem., 2012, 55, 8409-8417.
5. Manfredi, R. Calza, L. Extensively drug-resistant tuberculosis in patients recently immigrated from Eastern Europe. Microbiol. Ther. Public Health Feat. Clin. Microbiol. Infect., 2009, 15, S133.
6. World Health Organization. Definitions and reporting framework for tuberculosis revision. 2012.
7. Balaji, K. N., Schwander, S. K., Rich, E. A., Boom, W. H. Alveolar macrophages as accessory cells for human gamma-delta t-cells activated by mycobacterium-tuberculosis. J. Immunol., 1995, 154, 5959-5968.
8. Gonzalez-Juarrero, M., O'Sullivan, M. P. Optimization of inhaled therapies for tuberculosis: The role of macrophages and dendritic cells. Tuberculosis, 2011, 91, 86-92.
9. Palanisamy, G. S., Smith, E. E. Shanley, C. A., Ordway, D. J., Orme, I. M. Basaraba, R. J. Disseminated disease severity as a measure of virulence of Mycobacterium tuberculosis in the guinea pig model. Tuberculosis, 2008, 88, 295-306.
10. Chan, J. Chan, H. K. Prestidge, C. Denman, J. Young, P., Traini, D. A novel dry powder inhalable formulation incorporating three firstline anti-tubercular antibiotics. Eur. J. Pharm. Biopharm., 2013, 83, 285-292.
11. Gonzalez-Juarrero, M. Immunity to TB and targets for immunotherapy. Immunotherapy, 2012, 4(2), 187.
12. Orme, I. M. Cooper, A. M. Cytokine/chemokine cascades in immunity to tuberculosis. Immunol. Today, 1999, 20, 307-312.
13. Skeiky, Y. A. W., Sadoff, J. C. Advances in tuberculosis vaccine strategies. Perspectives, 2006, 4, 469-476.
14. Cayabyab, M. J., Macovei, L., Campos-Neto, A. Current and novel approaches to vaccine development against tuberculosis. Front. Cell. Infect. Microbiol., 2012, 2, 1-16.
15. Ulrichs, T., Kosmiadi, G. A., Trusov, V., Jorg, S., Pradl, L., Titukhina, M., Mishenko, V. Gushina, N. Kaufmann, S. H. E. Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung. J. Pathol., 2004, 204, 217-228.
16. Ordway, D., Henao-Tamayo, M., Gonzalez-Juarrero, M. O. I. M. Foamy macrophages within lung granulomas of mice infected with Mycobacterium tuberculosis express molecules characteristic of dendritic cells and antiapoptotic markers of the TNF receptorassociated factor family. J. Immunol., 2005, 175, 3873-3881.
17. Louw, G. E., Warren, R. M., Gey, V. P. N. C., McEvoy, C. R. E., Van Helden, P. D., Victor, T. C. A Balancing Act: Efflux/Influx in Mycobacterial Drug Resistance. Antimicrob. Agents Chemother., 2009, 53, 3181-3189.
18. World Health Organization. Treatment of tuberculosis 2012: guidelines, fourth edition. WHO/HTM/TB/2009. 420.
19. WHO Model List of Essential Medicines (http://www. who. int/medicines/publications/essentialmedicines/en/index. html).
20. Barry, P. J., O'Connor, T. M. Novel agents in the management of Mycobacterium tuberculosis disease. Curr. Med. Chem., 2007, 14, 2000-2008.
21. Garcia-Contreras, J, L. Sung, C., Muttil, P., Padilla, D., Telko, M., VerBerkmoes, J. L., Elbert, K. J., Hickey, A. J., Edwards, D. A. Dry Powder PA-824 Aerosols for Treatment of Tuberculosis in Guinea Pigs. Antimicrob. Agents Chemother., 2010, 54, 1436-1442.
22. Pandey, R., Khuller, G. K. Antitubercular inhaled therapy: opportunities, progress and challenges. J. Antimicrob. Chemother., 2005, 55, 430-435.
23. Turner, M. T., Haskal, R., McGowan, K., Nardell, E. Sabbag, R. Inhaled kanamycin in the treatment of multidrug-resistant tuberculosis: A study of five patients. Infect. Dis. Clin. Pract., 1998, 7, 49-53.
24. Adane, A. A., Alene, K. A., Koye, D. N., Zeleke, B. M. Non-Adherence to Anti-Tuberculosis Treatment and Determinant Factors among Patients with Tuberculosis in Northwest Ethiopia, in: PLOS One, 2013, pp. e78791.
25. Isoniazid, Tuberculosis, 2008, 88, 112-116.
26. Morde, M. A., Bajaj, A. N., Bhanushali, R. S. Rifampicin pulmospheres for pulmonary delivery. Indian J. Pharm. Sci., 2009, 71, 718-721.
27. Rifabutin. Tuberculosis, 2008, 88, 145-147.
28. Ethambutol. Tuberculosis, 2008, 88, 102-105.
29. Kayukova, L. A. Praliev, K. D. Main directions in the search for new antituberculous drugs (Review). Pharm. Chem. J., 2000, 34, 11-18.
30. Gatifloxacin. Tuberculosis, 2008, 88, 109-111.
31. Dumon, G. Trial of kanamycin aerosols associated with wetting or diffusing factors in the treatment of pulmonary tuberculosis. Revue de tuberculose et de pneumologie, 1961, 25, 41-52.
32. Padhi, B., Chougule, M. Misra, A. Aerosol performance of large respirable particles of amikacin sulfate produced by spray and freeze drying techniques. Curr. Drug Deliv., 2009, 6, 8-16.
33. Garcia-Contreras, L. Fiegel, J., Telko, M. J., Elbert, K., Hawi, A., Thomas, A., Ver Berkmoes, J., Germishuizen, W. A., Fourie, P. B., Hickey, A. J., Edwards, D. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob. Agents Chemother., 2007, 51, 2830-2836.
34. Leconte, P., Legallou, F., Potel, G., Struillou, L., Baron, D., Drugeon, H. B. Pharmacokinetics, toxicity, and efficacy of liposomal capreomycin in disseminated mycobacterium-avium beige mouse model. Antimicrob. Agents Chemother., 1994, 38, 2695-2701.
35. Schoubben, A., Blasi, P., Marenzoni, M. L., Barberini, L., Giovagnoli, S., Cirotto, C., Ricci, M. Capreomycin supergenerics for pulmonary tuberculosis treatment: Preparation, in vitro, and in vivo characterization. Eur. J. Pharm. Biopharm., 2013, 83, 388-395.
36. Yew, W. W., Cynamon, M., Zhang, Y. Emerging drugs for the treatment of tuberculosis. Expert Opin. Emerg. Drugs, 2011, 16, 1-21.
37. Cycloserine. Tuberculosis, 2008, 88, 100-101.
38. Ethionamide. Tuberculosis, 2008, 88, 106-108.
39. C. A. Ober, L. Kalombo, H. Swai, R. Gobta, Preparation of rifampicin/lactose composites by a supercritical antisolvent-drug excipient mixing technique for inhalation delivery. Powder Technol., 2013, 236, 132-138.
40. Son, Y., McConville, J. T. A new respirable form of rifampicin. Eur. J. Pharm. Biopharm., 2011, 78, 366-376.
41. Muttil, P., Wang, C. C., Hickey, A. J. Inhaled Drug Delivery for Tuberculosis Therapy. Pharm. Res., 2009, 26, 2401-2416.
42. Garcia-Contreras, L., Muttil, P., Fallon, J. K., Kabadi, M. Gerety, R. Hickey, A. J. Pharmacokinetics of Sequential Doses of Capreomycin Powder for Inhalation in Guinea Pigs. Antimicrob. Agents Chemother., 2012, 56, 2612-2618.
43. Misra, A., Hickey, A. J., Rossi, C., Borchard, G., Terada, H., Makino, K., Fourie, P. B., Colombo, P. Inhaled drug therapy for treatment of tuberculosis. Tuberculosis, 2011, 91, 71e81.
44. Gupta, A., Pandya, S. M., Mohammad, I. Agrawal, A. K., Mohan, M., Misra, A. Particulate Pulmonary Delivery Systems Containing Anti-Tuberculosis Agents, Critical Reviews in Therapeutic. Drug Carrier Systems, 2013, 30, 277-291.
45. NIH. 3 December 2003, posting date. Aerosol delivery of MTB and chemotherapeutics: pitfalls and plans. NIH, Bethesda, MD. http://www3. niaid. nih. gov/Biodefense/Research/AEROSOL/laurav ia. pdf., in.
46. Yapa, S. W. S., Li, J., Patel, K., Wilson, J. W., Dooley, M. J., George, J. Clark, D., Poole, S., Williams, E., Porter, C. J. H., Nation, R. L., McIntosh, M. P. Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration. Antimicrob. Agents Chemother., 2014 (published online ahead of print on 18 February 2014).
47. Claus, S. Weiler, C. Schiewe, J. Friess, W. How can we bring high drug doses to the lung? Eur. J. Pharm. Biopharm., 2014, 86 1-6.
48. Parikh, R., Patel, L., Dalwadi, S. Microparticles of rifampicin: comparison of pulmonary route with oral route for drug uptake by alveolar macrophages, phagocytosis activity and toxicity study in albino rats. Drug Deliv., 2013, 21(6), 406-11.
49. Lal, S., Singhal, S., Burley, D., Crossley, G. Effect of rifampicin and isoniazid on liver function. Br. Med. J., 1972, 1, 148-150.
50. Carlisle, R., Galambos, J. T. The relationship between conventional liver tests, quantitative function tests, and histopathology in cirrhosis. Dig. Dis. Sci., 1979, 243, 58-362.
51. Jawahar, N., Reddy, G. Nanoparticles: A novel pulmonary drug delivery system for tuberculosis. J. Pharm. Sci. Res., 2012, 4 1901-1906.
52. Taylor, G. Gumbleton, M. Aerosols for macromolecule delivery: Design challenges and solutions. Am. J. Drug Deliv., 2004, 2, 143-155.
53. Lee, S. H., Teo, J., Heng, D., Ng, W. K., Chan, H., Tan, R. B. H. Synergistic Combination dry powders for inhaled antimicrobial therapy: Formulation, characterization and in vitro evaluation. Eur. J. Pharm., 2013, 83, 275-284.
54. Dolovich, M. B., Dhand, R. Aerosol drug delivery: developments in device design and clinical use. Lancet, 2011, 377, 1032-1045.
55. Sou, T. Meeusen, E. N. de Veer, M., Morton, D. A. V., Kaminskas, L. M. McIntosh, M. P. New development in dry powder pulmonary vaccine delivery. Trends Biotechnol., 2011, 29, 191-198.
56. Young, P. M., Crapper, J., Philips, G., Sharma, K., Chan, H. K., Traini, D. Overcoming Dose Limitations Using the Orbital((R)) Multi-Breath Dry Powder Inhaler. J. Aerosol Med. Pulmonary Drug Deliv., 2014, 27, 138-147.
57. Feng, H. Zhang, L. Zhu, C. Genipin crosslinked ethyl cellulosechitosan complex microspheres for anti-tuberculosis delivery. Colloids Surfaces B: Biointerfaces, 2013, 103, 530-537.
58. Davies, G. R., Cerri, S. Richeldi, L. Rifabutin for treating pulmonary tuberculosis (Review), in: Cochrane Database Syst. Rev., 2007.
59. Patil-Gadhe, A., Pokharkar, V. Single step spray drying method to develop proliposomes for inhalation: A systematic study based on quality by design approach. Pulmonary Pharmacol. Ther., 2014, 27, 197-207.
60. Chan, J. G. Y., Bai, X., Traini, D. An update on the use of rifapentine for tuberculosis therapy. Expert Opin. Drug Deliv., 2014, 11, 421-431.
61. Chan, J. G. Y., Duke, C. C., Ong, H. X., Chan, J. C. Y., Tyne, A. S., Chan, H. K., Britton, W. J., Young, P. M., Traini, D. A novel inhalable form of rifapentine. J. Pharm. Sci., 2014, 103, 1411-1421.
62. Hickey, A. J., Misra, A., Fourie, P. B. Dry Powder Antibiotic Aerosol Product Development: Inhaled Therapy for Tuberculosis. J. Pharm. Sci., 2013, 102, 3900-7.
63. Dharmadhikari, A. S., Kabadi, M., Gerety, B., Hickey, A. J., Fourie, P. B., Nardell, E. Phase I, Single-Dose, Dose-Escalating Study of Inhaled Dry Powder Capreomycin: a New Approach to Therapy of Drug-Resistant Tuberculosis. Antimicrob. Agents Chemother., 2013, 57, 2613-2619.
64. Manion, J., Cape, S., McAdams, D. H., Rebits, L. G., Evans, S. Sievers, R. E. Inhalable Antibiotics Manufactured Through Use of Near-Critical or Supercritical Fluids. Aerosol. Sci. Technol., 2012, 46, 403-410.
65. Muttil, P., Kaur, J., Kumar, K., Yadav, A. B., Sharma, R., Misra, A. Inhalable microparticles containing large payload of antituberculosis drugs. Eur. J. Pharm. Sci., 2007, 32, 140-150.
66. Chan, J. G. Y., Tyne, A. S., Pang, A., Chan, H. K., Young, P. M., Britton, W. J., Duke, C. C., Traini, D. A Rifapentine-Containing Inhaled Triple Antibiotic Formulation for Rapid Treatment of Tubercular Infection. Pharm. Res., 2013, 1-15.
67. Adi, H., Larson, I. Stewart, P. J. Adhesion and redistribution of salmeterol xinafoate particles in sugar-based mixtures for inhalation. Intl. J. Pharm., 2007, 337, 229-238.
68. Weers, J., Clark, A., Challoner, P. High dose inhaled powder delivery: challenges and techniques, in: Dalby, R. N., Byron, P. R., Peart, J. Suman, J. D., Farr, S. J. (Eds.) Respiratory Drug Delivery IX, Davis Healthcare International Publishing (River Grove, IL, USA), Palm Desert, CA, USA, 2004, pp. 281-288.
69. Qui, Y. Adjei, A. L. Gupta, P. K. Absorption and bioavailability of inhaled peptides and proteins, in: Adjei, A. L., Gupta, P. K. (Eds.) Inhalation delivery of Therapeutic Peptides and Proteins, Mercel Dekker, Inc., New York., 1997.
70. Das, S., Behara, S., Bulitta, J., Morton, D., Larson, I., Stewart, P. Powder Strength Distributions for Understanding Deagglomeration of Lactose Powders. Pharm. Res., 2012, 29, 2926-2935.
71. Kendall, K., Stainton, C. Adhesion and aggregation of fine particles. Powder Technol., 2001, 121, 223-229.
72. Zhou, Q. T., Qu, L., Larson, I. Stewart, P. J. Morton, D. A. V. Improving aerosolization of drug powders by reducing powder intrinsic cohesion via a mechanical dry coating approach. Intl. J. Pharm., 2010, 394, 50-59.
73. Das, S. C., Luu, J., Morton, D. A. V., Stewart, P. A novel approach to develop high dose drug alone inhaler in: Drug Delivery to the Lungs 23 Conference, Edinburgh International Conference Centre, UK, 2013.
74. Das, S. C., Morton, D. A. V., Stewart, P. High Dose Drug Only Respiratory Delivery-novel approaches to understand aerosolisation of powders, in: Inhalation Asia, Hongkong, 2013.
75. Fourie, P. B., Germishuizen, W. A., Yong, Y. L., Edwards, D. A. Spray drying TB vaccines for pulmonary administration. Expert Opin. Biol. Ther., 2008, 8, 857-863.
76. Palazzo, F. Giovagnoli, S., Schoubben, A., Blasi, P., Rossi, C., Ricci, M. Development of a spray-drying method for the formulation of respirable microparticles containing ofloxacin-palladium complex. Intl. J. Pharm., 2013, 440, 273-282.
77. Seville, P., Li, H., Learoyd, T. Spray-dried powders for pulmonary drug delivery. Crit. Rev. Ther. Drug Carrier Systems, 2007, 24, 307-360.
78. Lawlor, C., O'Sullivan, M. P., Rice, B., Dillon, P., Gallagher, P. J., O'Leary, S., Shoyel, S., Kean, J. Cryan, S. A. Therapeutic aerosol bioengineering of targeted, inhaled microparticle formulations to treat Mycobacterium tuberculosis (MTb). J. Mater. Sci. Mater. Med., 2012, 23, 89-98.
79. Changsan, N., Chan, H. K., Separovic, F., Srichana, T. Physicochemical Characterization and Stability of Rifampicin Liposome Dry Powder Formulations for Inhalation. J. Pharm. Sci., 2009, 98, 628-639.
80. Misra, A., Jinturkar, K., Patel, D., Lalani, J., Chougule, M. Recent advances in liposomal dry powder formulations: Preparation and evaluation. Expert Opin. Drug Deliv., 2009, 6, 71-89.
81. Sethuraman, V. V., Hickey, A. J. Powder Properties and Their Influence on Dry Powder Inhaler Delivery of an Antituberculosis Drug. AAPS Pharm. Sci. Tech., 2002, 3, 1-10.
82. Muttil, P., Wang, C., Hickey, A. J. Inhaled drug delivery for tuberculosis therapy. Pharm. Res., 2009, 26, 2401-2416.
83. Booysen, L. L. I. J., Kalombo, L., Brooks, E., Hansen, R., Gilliland, J., Gruppo, V., Lungenhofer, P., Semete-Makokotlela, B., Swai, H. S., Kotze, A. F., Lenaerts, A., Du Plessis, L. H. In vivo/in vitro pharmacokinetic and pharmacodynamic study of spray-dried poly-(dl-lactic-co-glycolic) acid nanoparticles encapsulating rifampicin and isoniazid. Intl. J. Pharm., 2013, 444, 10-17.
84. Son, Y., McConville, J. Preparation of sustained release rifampicin microparticles for inhalation. J. Pharm. Pharmacol., 2012, 64, 1291-1302.
85. Kisich, K. O., Gelperina, S., Higgins, M. P., Wilson, S., Shipulo, E. Oganesyan, E., Heifets, L. Encapsulation of moxifloxacin within poly(butyl cyanoacrylate) nanoparticles enhances efficacy against intracellular Mycobacterium tuberculosis. Intl. J. Pharm., 2007, 345, 154-162.
86. Bhardwaj, A., Kumar, L. Narang, R. K., Murphy, R. S. R. Development and characterization of ligand-appended liposomes for multiple drug therapy for pulmonary tuberculosis. Artificial cells. Nanomed. Biotechnol., 2013, 41, 52-59.
87. Smith, I. J., Parry-Billings, M. The inhalers of the future? A review of dry powder devices on the market today. Pulm. Pharmacol. Ther., 2003, 16, 79-95.
88. Hirota, K., Hasegawa, T., Nakajima, T., Inagawa, H., Kohchi, C. Soma, G.-I., Makino, K., Terada, H. Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis. J. Control. Release, 2010, 142, 339-346.
89. Via, L., Deretic, D., Ulmer, R., Hibler, N., Huber, L., Deretic, V. Arrest of mycobacterial phagosome maturation is caused by a block in vesicle fusion between stages controlled by rab5 and rab7. J. Biol. Chem., 1997, 272, 13326-13331.
90. Ferrari, G., Langen, H., Naito, M., Pieters, J. A coat protein on phagosomes involved in the intracellular survival of mycobacteria. Cell, 1999, 97, 435-447.
91. Meenach, S. A., Anderson, K. W., Hilt, J. Z., McGarry, R. C., Mansour, H. M. Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer. Eur. J. Pharm. Sci., 2013, 49, 699-711.
92. Meenach, S. A. Vogt, F. G., Anderson, K. W., Hilt, J. Z., McGarry, R. C., Mansour, H. M. Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols. Int. J. Nanomed., 2013, 8, 275-293.
93. Ganguly, S., Moolchandani, V., Roche, J. A., Shapiro, P. S., Somaraju, S., Eddington, N. D., Dalby, R. N. Phospholipid-induced in vivo particle migration to enhance pulmonary deposition. J. Aerosol. Med. Pulmonary. Drug Deliv., 2008, 23, 181-187.
94. Lai, S. K., Wang, Y.-Y., Hanes, J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev., 2009, 61, 158-171.
95. Hu, C., Feng, H., Zhu, C. Preparation and characterization of rifampicin-PLGA microspheres/sodium alginate in situ gel combination delivery system. Colloids Surfaces B: Biointerfaces, 2012, 95, 162-169.
96. Kirby, D. J., Rosenkrands, I., Agger, E. M., Andersen, P., Coombes, A. G. A. Perrie Y. PLGA microspheres for the delivery of a novel subunit TB vaccine. J. Drug Target, 2008, 16, 282-293.
97. Kumar, G., Malhotra, S., Shafiq, N., Pandhi, P., Khuller, G. K., Sharma, S. In vitro physicochemical characterization and short term in vivo tolerability study of ethionamide loaded PLGA nanoparticles: Potentially effective agent for multidrug resistant tuberculosis. J. Microencapsulation, 2011, 28, 717-728.
98. Kumar, G. Shafiq, N. Malhotra, S. Drug-loaded PLGA nanoparticles for oral administration: Fundamental issues and challenges ahead. Crit. Rev. Ther. Drug Carrier Systems, 2012, 29, 149-182.
99. Lu, D., Garcia-Contreras, L., Xu, D., Kurtz, S. L., Liu, J., Braunstein, M., McMurray, D. N., Hickey, A. J. Poly (lactide-coglycolide) microspheres in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen 85B. Pharm. Res., 2007, 24, 1834-1843.
100. Ohashi, K., Kabasawa, T., Ozeki, T., Okada, H. One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticlecontaining mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis. J. Controlled Release, 2009, 135, 19-24.
101. Jain, P. V., Gudsoorkar, V. R., Jain, D. P., Salunke, K. Preparation and in vitro evaluation of spray dried microparticles of antitubercular drugs for pulmonary delivery. Intl. J. Pharm. Sci. Rev. Res., 2012, 12, 120-128.
102. Goldbach, P., Brochart, H., Stamm, A. Spray drying of liposomes for a pulmonary administration. I. Chemical stability of phospholipids. Drug Devel. Industrial Pharm., 1993, 19, 2611e2622.
103. Chougule, M., Padhi, B., Misra, A. Nano-liposomal dry powder inhaler of tacrolimus: preparation, characterization, and pulmonary pharmacokinetics. Intl. J. Nanomed., 2007, 675, e688.
104. Chougule, M., Padhi, B., Misra, A. Development of spray dried liposomal dry powder of dapsone. AAPS. Pharm. Sci. Tech., 2008, 9, 47e53.
105. Chougule, M. B., Padhi, B. K., Jinturkar, K. A., Misra, A. Development of dry powder inhalers. Recent Pat. Drug Deliv. Formul., 2007, 1, 11e21.
106. Shah, S. P., Misra, A. Liposomal amikacin dry powder inhalers: effect of fines in in vitro performance. AAPS. Pharm. Sci. Tech., 2004, 9e65.
107. Swaminathan, J., Ehrhardt, C. Liposomes for pulmonary drug delivery, in: Smyth, H. D. C., Hickey, A. J. (Eds.) Controlled Pulmonary Drug Delivery, Springer Verlag, Tiergartenstrasse 17, Heidelberg D-69121, Germany, 2011, pp. 313-334.
108. Vyas, S. P., Kannan, M. E., Jain, S., Mishra, V., Singh, P. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Intl. J. Pharm., 2004, 269, 37-49.
109. Willis, L. Hayes, D. Mansour, H. M. Therapeutic Liposomal Dry Powder Inhalation Aerosols for Targeted Lung Delivery. Lung, 2012, 190, 251-262.
110. Rojanarat, W., Nakpheng, T., Thawithong, E., Yanyium, N., Srichana, T. Inhaled pyrazinamide proliposome for targeting alveolar macrophages. Drug Deliv., 2012, 19, 334-345.
111. Rojanarat, W., Changsan, N., Tawithong, E., Pinsuwan, S., Chan, H. Srichana, T. Isoniazid Proliposome Powders for Inhalation-Preparation, Characterization and Cell Culture Studies. Int. J. Mol. Sci., 2011, 12, 4414-4431.
112. Schwartz, Y. S., Dushkin, M. I., Vavilin, V. A., Melnikova, E. V., Khoschenko, O. M., Kozlov, V. A., Agafonov, A. P., Alekseev, A. Y., Rassadkin, Y. Shestapalov, A. M., Azaev, M. S., Saraev, D. V., Filimonov, P. N., Kurunov, Y., Svistelnik, A. V., Krasnov, V. A., Pathak, A. Derrick, S. C., Reynolds, R. C., Morris, S., Blinov, V. M. Novel conjugate of moxifloxacin and carboxymethylated glucan with enhanced activity against Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2006, 50, 1982-1988.
113. Labiris, N. R. Dolovich, M. B. Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. J. Clin. Pharmacol., 2003, 56, 588-599.
114. Ishihara, K., Nomura, H., Mihara, T., Kurita, K., Iwasaki, Y., Nakabayashi, N. Why do phospholipid polymers reduce protein adsorption? J. Bioml. Materials Res., 1998, 39, 323-330.
115. Labiris, N. R., Dolovich, M. B. Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. J. Clin. Pharmacol., 2003, 56, 588-599.
116. Labiris, N. R. Dolovich, M. B. Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulation in therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol., 2003, 56, 600-612.
117. Mansour, H. M., Rhee, Y. S., Park, C. W., DeLuca, P. P. Lipid nanoparticulate drug delivery and nanomedicine, in: A. Moghis (Ed.) Lipids in Nanotechnology, American Oil Chemists Society (AOCS) Press, Urbana, Illinois, 2011, pp. 221-268.
118. Mansour, H. M., Sohn, M., Al-Ghananeem, A., DeLuca, P. P. Materials for pharmaceutical dosage forms: molecular pharmaceutics and controlled release drug delivery aspects. Intl. J. Mol. Sci., 2010, 11, 3298-3322.
119. Kaur, G. Narang, R. K., Rath, G., Goyal, A. K. Advances in Pulmonary Delivery of Nanoparticles, Artificial Cells. Blood Sub. Biotechnol., 2012, 40, 75-96.
120. Jaafar-Maalej, C., Elaissari, A., Fessi, H. Lipid-based carriers: Manufacturing and applications for pulmonary route. Expert Opin. Drug Deliv., 2012, 9, 1111-1127.
121. Kumar, B. P., Reddy, K., Reddy, V., Siva, P., Anusha, S. Solid lipid nano particles: A novel approach in drug delivery. J. Chem. Pharm. Sci., 2012, 5, 22-29.
122. Sivadasan, D., Madavan, B., Penmatsa, S. D., Bathini, S. T. Formulation and characterization of solid lipid nanoparticles of rifampicin. Erciyes Tip Dergisi, 35, 2013, 1-5.
123. Weber, S., Zimmer, A. Pardeike, J. Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: A review of the state of the art. Eur. J. Pharm. Biopharm., 2013, (in press).
124. Pandey, R., Khuller, G. K. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis, 2005, 85, 227-234.
125. Li, Y. Z., Sun, X., Gong, T., Liu, J., Zuo, J., Zhang, Z. R. Inhalable microparticles as carriers for pulmonary delivery of thymopentinloaded solid lipid nanoparticles. Pharm. Res., 2010, 27, 1977-1986.
126. Weber, S., Zimmer, A., Pardeike, J. Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: A review of the state of the art. Eur. J. Pharm. Biopharm., 2014, 86, 7-22.
127. Hwang, S. M., Kim, D. D., Chung, S. J., Shim, C. K. Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosis. J. Controlled Release, 2008, 129, 100e106.
128. Yadav, A. B., Singh, A. K., Verma, R. K., Mohan, M., Agrawal, A. K., Misra, A. The devil's advocacy: When and why inhaled therapies for tuberculosis may not work. Tuberculosis, 2011, 91, 65-66.